Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1996-04-15
1998-11-24
Feisee, Lila
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
435326, 435332, 4241301, 4241341, 4241411, 4241731, 4241561, 5303871, 53038822, 5303887, A61K 39395, C07K 1628, C12N 506, C12N 512
Patent
active
058403442
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a novel monoclonal antibody having the property of causing apoptosis on myeloid cells and being useful as medicine for myelocytic leukemia, and fragments thereof, and furthermore, relates to a hybridoma producing the monoclonal antibody.
Since the monoclonal antibodies of the present invention are useful as antibodies recognizing and identifying antigens causing apoptosis on myeloid cells specifically and besides have the property of causing apoptosis on myeloid cells, they may be used as medicine useful in the field of remedies for myelocytic leukemia utilizing the property.
BACKGROUND ART
Granulocyte colony-stimulating factors, for example, recombinant granulocyte colony-stimulating factors (rG-CSF), have been known primarily as humoral factors to stimulate the differentiation and proliferation of granulocyte cells, and it has been reported in an experiment upon mice in vivo that the administration of rG-CSF enhances the hematopoiesis of the bone marrow and in addition causes remarkable extramedullary hematopoiesis in the spleen to proliferate hematopoietic stem cells and all hematopoietic precursor cells in the spleen. And it has been thought as extramedullary hematopoietic mechanism in the spleen that hematopoiesis occurs due to a splenic hematopoietic microenvironment modifications according to the stimulation of rG-CSF to enhance hematopoietic potential.
Hence, the present inventors have noted splenic stromal cells administered rG-CSF with a view to clarifying the hematopoietic potential in the spleen, and established a hematopoietic stromal cell line (CF-1 cells) from the spleen of a mouse administered rG-CSF with a view to attempting the analysis of the enhancement of the hematopoietic potential by stromal cells with rG-CSF, and examined the potential effect on hematopoiesis using the hematopoietic stromal cells, and as a result, colony-stimulating activities in vitro and potency supportive of hematopoietic stem cells in
However, though some of splenic stromal cells have been established as a cell line (CF-1 cells), and cytological characteristics thereof have been examined, no specific antibody recognizing surface antigens thereof has been prepared so far, and characteristics thereof have been scarcely known yet.
Hence, the present inventors have engaged in assiduous studies with a view to developing specific antibodies capable of recognizing splenic stromal cells on the basis of the above information upon splenic stromal cells and the results of the studies, and prepared monoclonal antibodies using the splenic stromal cell lines as antigens for immunization, and as a result, novel monoclonal antibodies unreported so far have been obtained.
And as a result of examining the properties of the obtained monoclonal antibodies, the inventors have found surprisingly that they have the property of causing apoptosis on myeloid cells, which has led to the completion of the present invention.
DISCLOSURE OF INVENTION
It is the objective and purpose of the present invention to provide a novel monoclonal antibody having the property of causing apoptosis on myeloid cells and being useful as medicine for myelocytic leukemia, and fragments thereof, and in addition a hybridoma producing the monoclonal antibody.
The monoclonal antibody of the present invention is remarkably useful as an self-destruction of cells, phenomenon that a nuclear chromatin DNA is digested at a nucleosome unit (so-called ladder formation) to result in the death of cells! of myeloid cells and having a function of identifying them or a function of causing apoptosis on myeloid cells. Incidentally, myeloid cells include cells other than lymphoid cells, such as neutrophils, megakaryocytes, myeloblasts, myelocytes, mast cells, macrophages, monocytes and erythroblasts, and the myeloid cells according to the present invention also mean the same as mentioned above. No monoclonal antibody having the property of causing apoptosis on myeloid cells has been known so far, and hence the monoclonal ant
REFERENCES:
Itoh, N. et al Cell vol. 66 pp. 233-243, Jul. 1991.
Wust CJ et al Leukemia Res. vol. 15 pp. 497-506, 1991.
Oshim: Y et al J Immunol vol. 157 pp. 2909-2915, 1996.
Drebin JA Oncogene vol. 2 pp. 273-277, 1988.
Antibodies Harlow E & Lane D, Cold Spring Harbor Press, NY pp. 630-631, 1988.
Bansal Geetha P.
Chugai Seiyaku Kabushiki Kaisha
Feisee Lila
LandOfFree
Monoclonal antibodies having property of causing apoptosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies having property of causing apoptosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies having property of causing apoptosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1699458